Akili (NASDAQ:AKLI) versus Presbia (OTCMKTS:LENSF) Financial Survey

Akili (NASDAQ:AKLI) and Presbia (OTCMKTS:LENSF) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability.

Earnings and Valuation

This table compares Akili and Presbia’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akili	$1.95 million	17.46	-$59.49 million	($0.61)	-0.71
Presbia	N/A	N/A	N/A	N/A	N/A

Presbia has lower revenue, but higher earnings than Akili.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Akili and Presbia, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akili	0	0	1	0	3.00
Presbia	0	0	0	0	N/A

Akili currently has a consensus price target of $4.00, suggesting a potential upside of 825.93%. Given Akili’s higher probable upside, research analysts clearly believe Akili is more favorable than Presbia.

Institutional and Insider Ownership

53.1% of Akili shares are owned by institutional investors. 10.1% of Akili shares are owned by insiders. Comparatively, 74.2% of Presbia shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Akili and Presbia’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Akili	-2,492.04%	-79.93%	-59.16%
Presbia	N/A	N/A	N/A

Volatility & Risk

Akili has a beta of 1.72, suggesting that its stock price is 72% more volatile than the S&P 500. Comparatively, Presbia has a beta of 5.91, suggesting that its stock price is 491% more volatile than the S&P 500.

Summary

Presbia beats Akili on 5 of the 9 factors compared between the two stocks.

About Akili

Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.

About Presbia

Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company provides the refractive lens for patient surgeries, as well as accessories for procedures. It primarily operates in the United States, South Korea, Australia, Italy, the Netherlands, Ireland, Canada, and Germany. The company was founded in 2014 and is headquartered in Dublin, Ireland.